The mission of the Analgesic, Anesthetic, and Addiction Clinical Trial Translations, Innovations, Opportunities, and Networks (ACTTION) public-private partnership with the United States Food and Drug Administration (FDA) is to identify, prioritize, sponsor, coordinate, and promote innovative activities — with a special interest in optimizing clinical trials — that will expedite the discovery and development of improved analgesic, anesthetic, addiction, and peripheral neuropathy treatments for the benefit of the public health.

ACTTION is a multi-year, multi-phase initiative that is closely aligned with the FDA's Critical Path Initiative. This public-private partnership has been designed to streamline the discovery and development process for new analgesic, anesthetic, addiction, and peripheral neuropathy medications and to more generally accelerate the development of treatments with improved efficacy and safety.

The key objectives of ACTTION involve initiating and supporting strategic collaborations among a broad spectrum of stakeholders — including, but not limited to, academia, the FDA and other government agencies, industry, professional organizations, patient advocacy groups, foundations, and philanthropic organizations — with the goals of sharing data and innovative thinking about the development of novel therapeutics. These strategic collaborations involve a wide range of research projects and other activities, for example, scientific workshops, consensus meetings, and in-depth analyses of clinical trial data to determine the effects of research methods on study assay sensitivity and efficiency.

ACTTION is intended to have benefits that are international in scope. To represent the bridges that ACTTION is establishing among its diverse stakeholders, this website is illustrated with watermarks of two bridges that share the distinction of connecting different continents. Directly below is the First Bosphorus Bridge in Istanbul, Turkey, which connects Europe and Asia; on the Contact Us webpage is the Leifur Eiriksson Bridge in Iceland's Reykjanes peninsula, which spans a rift valley between the North American and European continental plates.


May 11, 2016: Drs. Eisenach and Neogi to Serve as Co-Chairs of ACTTION Steering and Executive Committees

ACTTION is pleased to announce that James C. Eisenach, MD, will serve as Co-Chair of the ACTTION Steering and Executive Committees representing the American Society of Anesthesiologists (ASA) and that Tuhina Neogi, MD, will serve as Co-Chair of the ACTTION Steering and Executive Committees representing the Osteoarthritis Research Society International (OARSI). ACTTION looks forward to collaborating with Drs. Eisenach and Neogi and is confident that their expertise will contribute greatly to its activities. ACTTION is indebted to Drs. Denham Ward and Joanne Jordan, who have expertly filled these roles for several years and whose efforts on behalf of ACTTION are greatly appreciated.

April 11, 2016: FDA Releases Funding Opportunity Announcement for ACTTION

The FDA released a Funding Opportunity Announcement (FD-16-047) "to provide support for developing and maintaining an organizational infrastructure to support a broad-based public-private partnership" under FDA's ACTTION Initiative. The announcement indicates that up to one award will be made and that the maximum project period is five years. ACTTION is currently preparing an application in response to this funding announcement.

April 10, 2016: Overviews of ACTTION Presented at 3 Recent Meetings

Robert Dworkin, PhD, ACTTION Director, presented overviews of the ACTTION public-private partnership at recent meetings of the Measures for Justice Institute (April 10-11, 2016), Pediatric Anesthesia and Neurodevelopment Assessment (PANDA) Study and SmartTots public-private partnership (April 16-17, 2016), and Evolution Summit for Best Practices in North American Clinical Trials (May 9-11, 2016).